Fig. 4
From: Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities
TNBC response to metabolic modulators. a Schematic of metabolic pathways and the points at which chemical inhibitors or activators act. b–d Viability measurements of cells following 48 h of treatment with indicated chemicals: 25 mM 2-DG, 200 μM 6-AN, 1 μM rotenone, 10 mM metformin, and 1 mM AICAR. Data are viability averages from one representative experiment with error bars representing SD. Asterisks represent significance compared to vehicle control (p ≤ 0.01)